MTVA
Price:
$0.665
Market Cap:
$16.10M
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs incl...[Read more]
Industry
Biotechnology
IPO Date
2016-08-05
Stock Exchange
NASDAQ
Ticker
MTVA
According to MetaVia Inc.’s latest financial reports and current stock price. The company's current ROE is -212.00%. This represents a change of 262.12% compared to the average of -58.55% of the last 4 quarters.
The mean historical ROE of MetaVia Inc. over the last ten years is -190.57%. The current -212.00% ROE has changed 11.25% with respect to the historical average. Over the past ten years (40 quarters), MTVA's ROE was at its highest in in the March 2016 quarter at 354.04%. The ROE was at its lowest in in the December 2020 quarter at -270.86%.
Average
-190.57%
Median
-89.72%
Minimum
-847.88%
Maximum
116.88%
Discovering the peaks and valleys of MetaVia Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.10%
Maximum Annual ROE = 116.88%
Minimum Annual Increase = -248.34%
Minimum Annual ROE = -847.88%
| Year | ROE | Change |
|---|---|---|
| 2024 | -347.90% | 365.49% |
| 2023 | -74.74% | 16.38% |
| 2022 | -64.22% | -38.67% |
| 2021 | -104.71% | -74.59% |
| 2020 | -412.02% | 137.64% |
| 2019 | -173.38% | -248.34% |
| 2018 | 116.88% | -113.79% |
| 2017 | -847.88% | 1.10% |
| 2016 | -70.70% | -196.93% |
| 2015 | 72.93% | 21.02% |
The current ROE of MetaVia Inc. (MTVA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-162.28%
5-year avg
-200.72%
10-year avg
-190.57%
MetaVia Inc.’s ROE is greater than Lisata Therapeutics, Inc. (-78.18%), greater than NuCana plc (-580.99%), greater than Exicure, Inc. (-110.40%), greater than Enlivex Therapeutics Ltd. (-62.91%), greater than Klotho Neurosciences, Inc. (-201.59%), greater than Passage Bio, Inc. (-103.87%), less than Clearside Biomedical, Inc. (65.87%), less than CASI Pharmaceuticals, Inc. (358.32%), greater than Sonnet BioTherapeutics Holdings, Inc. (-4648.06%), greater than CollPlant Biotechnologies Ltd. (-102.03%),
| Company | ROE | Market cap |
|---|---|---|
| -78.18% | $17.90M | |
| -580.99% | $26.90M | |
| -110.40% | $42.96M | |
| -62.91% | $28.19M | |
| -201.59% | $25.82M | |
| -103.87% | $29.19M | |
| 65.87% | $4.97M | |
| 358.32% | $15.16M | |
| -4648.06% | $8.43M | |
| -102.03% | $26.70M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MetaVia Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like MetaVia Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is MetaVia Inc.'s ROE?
How is the ROE calculated for MetaVia Inc. (MTVA)?
What is the highest ROE for MetaVia Inc. (MTVA)?
What is the 3-year average ROE for MetaVia Inc. (MTVA)?
What is the 5-year average ROE for MetaVia Inc. (MTVA)?
How does the current ROE for MetaVia Inc. (MTVA) compare to its historical average?